Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Orphan Drug Exclusion Seems Untenable, Sen. Hatch Tells HRSA

This article was originally published in The Pink Sheet Daily

Executive Summary

Following the Health Resources and Services Administration’s final rule on excluding orphan drugs from the 340B discount, Sen. Hatch writes to object to the agency’s interpretation of the statutory language.


Related Content

340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request
Senior Senators Seek Details On Government Audits Of 340B Entities





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts